Ophthalmic compositions for treating ocular
Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.
1. An ophthalmic composition comprising lotilaner and a pharmaceutically acceptable vehicle,
wherein the ophthalmic composition is in eye drop form,
wherein the ophthalmic composition is sterile and nonirritating to the eye, and
wherein the lotilaner is present from about 0.10% to about 0.50% by weight with respect to the total weight of the composition.
2. The ophthalmic composition of claim 1 , wherein the pharmaceutically acceptable vehicle further comprises a preservative agent.
3. The ophthalmic composition of claim 1 , wherein the lotilaner is the sole active ingredient of the ophthalmic composition.
4. The ophthalmic composition of claim 1 , wherein the ophthalmic composition does not comprise tea tree oil.
5. The ophthalmic composition of claim 1 , wherein the ophthalmic composition further comprises castor oil.
6. The ophthalmic composition of claim 5 , wherein the castor oil comprises hydrogenated castor oil.
7. The ophthalmic composition of claim 1 , comprising from between about 0.15% and about 0.40% of the lotilaner by weight with respect to the total weight of the composition.
8. The ophthalmic composition of claim 6 , comprising about 0.25% of the lotilaner by weight with respect to the total weight of the composition.
9. The ophthalmic composition of claim 1 , wherein the ophthalmic composition is formulated to be topically administered at least once daily for at least about 4 weeks.
10. The ophthalmic composition of claim 8 , wherein the ophthalmic composition is formulated to be topically administered at least twice daily for at least about 4 weeks.
11. The ophthalmic composition of claim 9 , wherein the ophthalmic composition is formulated to be topically administered at least twice daily for at least about 6 weeks.
12. The ophthalmic composition of claim 1 , wherein the ophthalmic composition is formulated to be topically administered in a volume of between 25-50 microliters at least one time daily.
13. The ophthalmic composition of claim 1 , wherein the ophthalmic composition is formulated to be topically administered in a volume of between 25-50 microliters at least twice daily for at least six weeks.
14. The ophthalmic composition of claim 1 , wherein the ophthalmic composition is for use in treating an ocular Demodex infestation in a human patient.
15. The ophthalmic composition of claim 14 , wherein the ocular Demodex infestation comprises blepharitis.
16. The ophthalmic composition of claim 14 , wherein the ocular Demodex infestation comprises ocular rosacea.
17. The ophthalmic composition of claim 14 , wherein the ocular Demodex infestation comprises Meibomian gland dysfunction.
18. The ophthalmic composition of claim 14 , wherein the ocular Demodex infestation comprises ocular surface disease.
19. The ophthalmic composition of claim 14 , wherein the ocular Demodex infestation comprises dry eye disease.
20. The ophthalmic composition of claim 14 , wherein the ocular Demodex infestation comprises madarosis.